Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of ARO-APOC3 in adults with dyslipidemia
NL-OMON53567Phase 2Not yet recruiting
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- May 2023
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of plozasiran in dyslipidemia and hypertriglyceridemia (4 arms), sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Incidence of treatment-emergent adverse events. Planned start May 2023; status: not yet recruiting.
02
Drugs
plozasiran
03
Conditions
dyslipidemiahypertriglyceridemia
Beyond the preview
Go deeper on NL-OMON53567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53567.